Lexicon Pharmaceuticals

LXRX62

Penny Stock

$0.82arrow_drop_down0.19%-$0.00

Penny Stock

LXRX62

$0.82

arrow_drop_down0.19%-$0.00

Penny Stock

Performance History

Key Stats
Open	$0.82
Prev. Close	$0.81
EPS	-0.74
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$296.49M
PE Ratio	-

	LOW	HIGH
Day Range	0.78	0.85
52 Week Range	0.63	3.73

Ratios







EPS	-0.74

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals Inc (LXRX) is a biopharmaceutical company that focuses on the discovery and development of innovative medicines for the treatment of various diseases. With a rich history and a strong track record of success, Lexicon Pharmaceuticals has established itself as a leader in the field of pharmaceutical research and development.

One of the key factors that sets Lexicon Pharmaceuticals apart from its competitors is its commitment to smart analysis. By utilizing advanced data analytics and cutting-edge technology, the company is able to gain valuable insights that inform its decision-making process. This allows Lexicon Pharmaceuticals to identify promising drug candidates and bring them to market more efficiently.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Lonnel Coats
Headquarters: The Woodlands
Employees: 135
Exchange: NASDAQ

add Lexicon Pharmaceuticals to watchlist

Keep an eye on Lexicon Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Lexicon Pharmaceuticals 's (LXRX) price per share?

The current price per share for Lexicon Pharmaceuticals (LXRX) is $0.82. The stock has seen a price change of -$0 recently, indicating a -0.2% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Lexicon Pharmaceuticals (LXRX)?

For Lexicon Pharmaceuticals (LXRX), the 52-week high is $3.73, which is 354.77% from the current price. The 52-week low is $0.64, the current price is 28.76% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Lexicon Pharmaceuticals (LXRX) a growth stock?

Lexicon Pharmaceuticals (LXRX) has shown an average price growth of -3.4% over the past three years. It has received a score of 7 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Lexicon Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Lexicon Pharmaceuticals (LXRX) stock price performance year to date (YTD)?

As of the latest data, Lexicon Pharmaceuticals (LXRX) has a year-to-date price change of -48.42%. Over the past month, the stock has experienced a price change of -55.9%. Over the last three months, the change has been -53.66%. Over the past six months, the figure is -51.47%. Looking at a longer horizon, the five-year price change stands at -76.63%.

help

Is Lexicon Pharmaceuticals (LXRX) a profitable company?

Lexicon Pharmaceuticals (LXRX) has a net income of -$177.12M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 92.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.64K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.2M, although specific revenue growth data is currently not available. The gross profit is $1.12M. Operating income is noted at -$171.75M. Furthermore, the EBITDA is -$210.55M.

help

What is the market capitalization of Lexicon Pharmaceuticals (LXRX)?

Lexicon Pharmaceuticals (LXRX) has a market capitalization of $296.5M. The average daily trading volume is 0.81, indicating the stock's liquidity and investor engagement.

News

ZYNQUISTA

SOTAGLIFLOZIN

TYPE 1 DIABETES

CHRONIC KIDNEY DISEASE

FDA ADVISORY COMMITTEE

Oct 31, 2024

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

LEXICON PHARMACEUTICALS

SOTAGLIFLOZIN

HYPERTROPHIC CARDIOMYOPATHY

CLINICAL TRIAL

Sep 27, 2024

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

SOTAGLIFLOZIN

TYPE 2 DIABETES

CONTINUOUS GLUCOSE MONITORING

TIME-IN-RANGE

Sep 10, 2024

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

SOTAGLIFLOZIN

TYPE 1 DIABETES

CHRONIC KIDNEY DISEASE

LEXICON PHARMACEUTICALS

Aug 7, 2024

Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists

Jun 21, 2024

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

HEALTH

CLINICAL STUDY

Jun 21, 2024

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes